These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32256050)

  • 1. Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition.
    Yu M; Peng L; Liu P; Yang M; Zhou H; Ding Y; Wang J; Huang W; Tan Q; Wang Y; Xie W; Kong H; Wang H
    Drug Des Devel Ther; 2020; 14():1191-1202. PubMed ID: 32256050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paeoniflorin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing TAK1-MAPK/NF-κB pathways.
    Yu M; Wu X; Wang J; He M; Han H; Hu S; Xu J; Yang M; Tan Q; Wang Y; Wang H; Xie W; Kong H
    Int J Med Sci; 2022; 19(4):681-694. PubMed ID: 35582418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells.
    Liu P; Huang W; Ding Y; Wu J; Liang Z; Huang Z; Xie W; Kong H
    Drug Des Devel Ther; 2021; 15():1653-1666. PubMed ID: 33935492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
    Zhao H; Wang Y; Zhang X; Guo Y; Wang X
    Toxicol Appl Pharmacol; 2020 Jan; 386():114827. PubMed ID: 31734320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
    Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of pulmonary arterial hypertension.
    Suresh K; Servinsky L; Jiang H; Bigham Z; Zaldumbide J; Huetsch JC; Kliment C; Acoba MG; Kirsch BJ; Claypool SM; Le A; Damarla M; Shimoda LA
    Am J Physiol Lung Cell Mol Physiol; 2019 Nov; 317(5):L639-L652. PubMed ID: 31461316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-27a promotes endothelial-mesenchymal transition in hypoxia-induced pulmonary arterial hypertension by suppressing BMP signaling.
    Liu T; Zou XZ; Huang N; Ge XY; Yao MZ; Liu H; Zhang Z; Hu CP
    Life Sci; 2019 Jun; 227():64-73. PubMed ID: 31004656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension.
    Sun XQ; Peters EL; Schalij I; Axelsen JB; Andersen S; Kurakula K; Gomez-Puerto MC; Szulcek R; Pan X; da Silva Goncalves Bos D; Schiepers REJ; Andersen A; Goumans MJ; Vonk Noordegraaf A; van der Laarse WJ; de Man FS; Bogaard HJ
    Am J Respir Cell Mol Biol; 2021 Mar; 64(3):331-343. PubMed ID: 33264068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mineralocorticoid receptor antagonist treatment of established pulmonary arterial hypertension improves interventricular dependence in the SU5416-hypoxia rat model.
    Lu M; Chen LY; Gairhe S; Mazer AJ; Anderson SA; Nelson JNH; Noguchi A; Siddique MAH; Dougherty EJ; Zou Y; Johnston KA; Yu ZX; Wang H; Wang S; Sun J; Solomon SB; Vanderpool RR; Solomon MA; Danner RL; Elinoff JM
    Am J Physiol Lung Cell Mol Physiol; 2022 Mar; 322(3):L315-L332. PubMed ID: 35043674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Hypertension.
    Imano H; Kato R; Nomura A; Tamura M; Yamaguchi Y; Ijiri Y; Wu H; Nakano T; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Asahi M; Hayashi T
    Biol Pharm Bull; 2021 May; 44(5):669-677. PubMed ID: 33612567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to-Mesenchymal Transition in Human Right Ventricular Failure.
    Park JF; Clark VR; Banerjee S; Hong J; Razee A; Williams T; Fishbein G; Saddic L; Umar S
    Circ Heart Fail; 2021 Feb; 14(2):e007058. PubMed ID: 33541093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Benefit of the Association of Lodenafil with Mesenchymal Stem Cells on Hypoxia-induced Pulmonary Hypertension in Rats.
    Silva MMCD; Alencar AKN; Silva JSD; Montagnoli TL; Silva GFD; Rocha BS; Montes GC; Mendez-Otero R; Pimentel-Coelho PM; Vasques JF; Trahez MM; Sudo RT; Zapata-Sudo G
    Cells; 2020 Sep; 9(9):. PubMed ID: 32961896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penetrance of Severe Pulmonary Arterial Hypertension in Response to Vascular Endothelial Growth Factor Receptor 2 Blockade in a Genetically Prone Rat Model Is Reduced by Female Sex.
    Chaudhary KR; Deng Y; Yang A; Cober ND; Stewart DJ
    J Am Heart Assoc; 2021 Aug; 10(15):e019488. PubMed ID: 34315227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Mendes-Ferreira P; Adão R; Brás-Silva C; Kinsella BT
    Eur J Pharmacol; 2020 Dec; 889():173658. PubMed ID: 33121950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.
    Tian S; Cai Z; Sen P; van Uden D; van de Kamp E; Thuillet R; Tu L; Guignabert C; Boomars K; Van der Heiden K; Brandt MM; Merkus D
    Am J Physiol Heart Circ Physiol; 2022 Nov; 323(5):H958-H974. PubMed ID: 36149769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactive oxygen species induced Ca
    Suresh K; Servinsky L; Jiang H; Bigham Z; Yun X; Kliment C; Huetsch J; Damarla M; Shimoda LA
    Am J Physiol Lung Cell Mol Physiol; 2018 May; 314(5):L893-L907. PubMed ID: 29388466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats.
    Shoji H; Yoshida Y; Sanada TJ; Naito A; Maruyama J; Zhang E; Sumi K; Sakao S; Maruyama K; Hidaka H; Tatsumi K
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RV-specific Targeting of Snai1 Rescues Pulmonary Hypertension-induced Right Ventricular Failure by Inhibiting EndMT and Fibrosis
    Banerjee S; Onwunyi VRC; Hong J; Martineau S; Fishbein GA; Bonnet SB; Provencher S; Bonnet S; Umar S
    bioRxiv; 2024 May; ():. PubMed ID: 38746200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.